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ABSTRACT 
 
Prostate cancer is the most common malignancy and the second leading cause of cancer 
mortality in men in the United States, with 240,000 cases diagnosed and 30,000 deaths annually. 
It is a significant burden for the United States population and health care system due to the 
disease prevalence, mortality, effects on health related quality of life, as well as cost of 
treatment. Many different treatment options are available for localized, non-metastatic prostate 
cancer, such as active surveillance, radical prostatectomy, and radiation therapy, with newer and 
costlier treatment options being developed. Comparative effectiveness research between these 
forms of treatment is imperative to determine differences in survival outcomes, health related 
quality of life, and costs. Here, we reviewed the literature for the frequency of repeat biopsy in 
prostate cancer patients receiving active surveillance and effects on rate of disease progression, 
and found insufficient evidence regarding this. Additionally, due to the importance of baseline 
comorbid conditions in men with prostate cancer in terms of treatment decision making, health 
related quality of life, and survival outcomes, we conducted a prospective study of 881 men in 
North Carolina with localized prostate cancer to compare patient versus physician reporting of 
comorbidities. We calculated percent agreement and its kappa statistic between patient and 
physician-report for 20 commonly used comorbidities in cancer research. We found that overall, 
agreement between patient and physician reporting of common comorbidities in newly-
diagnosed prostate cancer patients is moderate. In research studies, whether physician reporting, 
patient reporting, or both should be used to inform treatment decision making and predict 
survival outcomes is unclear.  
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Localized Prostate Cancer Patients on Active Surveillance: How Frequently 
Should We Biopsy Them? A Systematic Review 
 
ABSTRACT 
 
Background: Active surveillance is a strategy in treating low-risk localized prostate cancer 
patients which defers treatment and monitors patients for disease progression. It is unclear what 
the optimal surveillance schedule should be. This review assesses the literature for frequency of 
surveillance biopsy and how that affects detection of disease progression.  
Methods: One author performed a systematic review of the literature on active surveillance 
strategies which used different frequencies of surveillance biopsy using PubMED. The articles 
were quality rated for internal validity, and external validity. 
Results: Twelve (12) studies met the inclusion criteria. Only one study directly assessed the risk 
of disease progression in relation to the timing of the repeat biopsy, (hazard ratio = 0.40, 95% CI 
= 0.56-1.58) when the repeat biopsy was performed within 6 months. The remaining studies 
assessed a mix of probability of disease progression, probability of meeting active surveillance 
criteria at given time points, percentage of patients who progressed, rate of intervention in 
patients, and percentage of patients receiving a repeat biopsy without directly analyzing timing 
of repeat biopsies during active surveillance. 
Conclusions: There is insufficient evidence regarding frequency of surveillance biopsy in 
prostate cancer patients on active surveillance. Future studies directly comparing disease 
progression or survival rates with frequency of biopsy are needed to fully assess the optimal 
schedule for surveillance biopsies.   
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INTRODUCTION 
 
 Prostate cancer is the most common cancer and the second leading cause of cancer 
mortality in men.1,2 However, unlike other cancers, such as lung or colorectal, there is a wide gap 
between the incidence and mortality rates of prostate cancer, as more than 240,000 cases are 
diagnosed yearly compared to roughly 30,000 deaths annually.1-3 The widespread advent of 
prostate-specific antigen (PSA) testing for the detection of prostate cancer resulted in a 
significantly higher incidence without similar increases or decreases in mortality.4,5 This has 
raised concerns regarding overdiagnosis, since many of these cancers are localized, small 
volume, and low grade, and would not have otherwise resulted in any clinical symptoms.4,5 
Overdiagnosis rates of prostate cancer have been estimated to be between 27% and 56%.4,6 
Unfortunately, the natural history of prostate cancer is heterogeneous and not well understood.3 
While some patients may benefit from radical treatment, others may not; as they may suffer from 
side effects of treatment for a potentially indolent cancer.7 
More than 90% of newly-diagnosed prostate cancer patients have localized and 
potentially curable disease.1 There are many different types of treatment options available for 
patients with localized prostate cancer, including radical prostatectomy, radiation therapy, and 
active surveillance.5 While radical prostatectomy, external beam radiotherapy, and brachytherapy 
are considered curative therapies for low-risk prostate cancer, they may result in long-term 
urinary, bowel, and sexual dysfunction, harming patient quality of life.5,8 An alternative strategy 
to these curative methods is active surveillance, which defers treatment and actively monitors 
low risk patients for disease progression, at which point curative treatment is offered.5,9 
 Progression is monitored with a variety of tools, including digital rectal examination 
(DRE), PSA, rebiopsy, and transrectal ultrasound (TRUS).7 The rationale behind this is most 
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men with prostate cancer will not benefit from invasive treatment, and this allows 
individualization of therapy based on the risk of clinically significant cancer.10 With this 
strategy, overtreatment of prostate cancer may be reduced, saving patients from the side effects 
of treatment as well as saving health resources spent on curative therapy.10 
Active surveillance strategies vary in terms of which follow-up criteria (DRE, PSA, 
rebiopsy, and/or TRUS) to use, and how often those tools are used.7 Prostate biopsies have 
associated harms, including pain and discomfort, rectal bleeding, change in urine flow, and 
infection, which may lead to urosepsis and death.11 Out of the various aforementioned follow-up 
criteria, prostate biopsy provides the most objective measure of cancer progression.12 Therefore, 
therefore the frequency of prostate biopsies should balance the benefit of potential detection of 
cancer progression with the harms of potential side effects. At the time of this review, it is 
unclear what the optimal surveillance schedule should be. The aim of this review is to examine 
men with localized prostate cancer undergoing active surveillance, and if there are any 
differences in the rate of detection of disease progression requiring intervention, when rebiopsy 
is performed at intervals less than one year after diagnosis compared to every one year or more 
after diagnosis. 
 
METHODS 
Key questions 
Key question 1: Which studies of men with localized prostate cancer undergoing active 
surveillance assess risk of progression requiring active treatment? 
Key question 2: What is the optimal frequency of performing rebiopsy in patients with localized 
prostate cancer undergoing active surveillance? 
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Eligibility criteria 
 For this review, I limited the population of interest to men with localized (node negative, 
non-metastatic) prostate cancer who are undergoing or have undergone an active surveillance 
protocol. I chose to exclude men who have previously been treated for prostate cancer because 
the management and treatment of recurrent prostate cancer is different from that of the initial 
cancer. The intervention and comparator of interest focus on the frequency of prostate biopsy 
after diagnosis has already been established and after the patient and provider choose to undergo 
active surveillance. For this review, I chose to compare a one-year or more interval with less than 
1 year. The outcome of interest is detection of disease progression requiring active treatment in 
the form of surgery or radiation. Although the optimal outcome of interest is benefit in survival 
or quality of life, these data are unlikely to be available as the natural history of prostate cancer 
can be very long. Active treatment is instead a surrogate marker as treatment may result in 
quality of life effects in terms of urinary, bowel, and sexual dysfunction.8 I chose to examine 
articles published in the past 10 years (after January 1st, 2004), as prostate cancer detection and 
treatment methods have evolved greatly. Studies must be performed in Western countries, as 
these populations are more generalizable to the United States. For inclusion the studies must be 
longitudinal studies. These predetermined inclusion and exclusion criteria are included in the 
PICOTTSS table shown in Table 1. 
 
Data sources and searches 
 To identify articles relevant to the focused question, I searched the MEDLINE database 
for studies on men with localized prostate cancer undergoing an active surveillance protocol 
from January 2004 to April 2014. Figure 1 below shows the search and selection process. I 
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limited my search to studies in English only. I looked for longitudinal studies that studied men 
with localized prostate cancer who have been on active surveillance, with data on progression of 
disease detected requiring treatment. For the MEDLINE search I used the focused MeSH terms 
“Prostatic Neoplasm” or “Prostate Specific Antigen” or the non-MeSH term “Prostate Cancer” 
combined with the non-MeSH terms “Active Surveillance” and “Longitudinal Studies.” The 
search strategy in MEDLINE is as follows: ((((((prostatic neoplasm[MeSH Major Topic]) OR 
prostate specific antigen[MeSH Major Topic] OR prostate cancer) AND “active surveillance”))) 
AND longitudinal studies). This yielded 141 results. Applying the filters “Humans,” and 
“English,” narrowed the results to 132. After limiting the studies to those after 2004, this further 
narrowed the results to 131. Additionally, I augmented my search by hand-searching the 
reference lists of relevant studies as well as review articles to find any other studies that met the 
inclusion criteria.  
 
Study selection 
 I selected and reviewed titles and abstracts of articles retrieved for my focused question 
in a systematic manner. I used predetermined inclusion and exclusion criteria listed in Table 1. I 
pulled full text articles for review if the title and abstract seemed relevant for the focused 
question. These were then reviewed to see if eligibility criteria were still met. I identified one 
review article in my hand search which listed 7 other studies relevant to the key question. Out of 
these, 4 were duplicate articles, and the other 3 were included for full text analysis. Studies that 
had updated versions found in the search were excluded as well. To be included, the studies had 
to be longitudinal studies of men with localized prostate cancer undergoing active surveillance, 
from which data on frequency of biopsy and possible disease progression could be extracted. 
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These studies must have been published in English. The study selection was performed by a 
single reviewer, however, it would have used two reviewers if additional time and resources 
were made available.  
 
Data extraction process 
 I developed a data extraction sheet to gather relevant data. These include sample size, 
participant characteristics (such as mean/median age, mean/median baseline PSA levels, 
mean/median Gleason scores, etc.), criteria for active surveillance, criteria for progression, 
frequency of biopsy after active surveillance enrollment, study results (including median follow-
up time, percentage of patients who progressed, percentage of patients that underwent active 
treatment, and survival outcomes if present), and overall conclusions about the study.   
 
Quality assessment and risk of bias in individual studies 
 I reviewed the full-text articles meeting all eligibility criteria and independently rated 
their quality with a single reviewer method. Double review would have been used if adequate 
time and resources were available. I rated the internal validity of the articles by assessing each 
for selection bias, measurement bias, and confounding. I assigned grades of “low,” “moderate,” 
and “high” for potential sources of bias. I also graded each study for the external validity. The 
studies were rated overall as “good,” “fair,” or “poor.” In order to qualify for a rating of “good,” 
a study must be well-designed with no more than low risk for selection bias, measurement bias, 
and confounding. A “fair” rating was given if potential for selection bias, measurement bias, and 
confounding was mostly moderate. Studies were rated as “poor” if there was excessive risk of 
bias.  
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Synthesis of results and data analysis 
 I combined all relevant abstracted data from the included studies qualitatively and 
quantitatively in a narrative and table format. Given that study designs, participants, active 
surveillance initiation criteria, frequency of rebiopsy, and reported outcomes were markedly 
varied, I chose to focus on describing the studies, results, applicability, and limitations in a 
qualitative synthesis analysis rather than use a meta-analysis.  
 
Role of funding Source(s) 
 There was no specified funding for this particular review and there are no known 
conflicts of interest related to this review. 
 
RESULTS 
Search results 
 The initial PubMed search returned 131 articles for review. A review article found during 
the search process listed another 7 articles, 4 of which were duplicated from the PubMed search. 
22 full-text articles were assessed for eligibility, and out of these, 10 papers were excluded 
because they were previous non-updated versions of studies that were already included. As such, 
12 total articles meeting the inclusion criteria were used in this systematic review (Figure 1). 
 
Study characteristics 
 All studies used in this review are longitudinal studies (Table 2). The main purpose of the 
studies varied, although 8 of the 12 studies aimed to describe the results of active surveillance in 
various patient populations. Other papers studied the role of immediate confirmatory biopsies or 
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repeated biopsies. 6 studies used 1 year or less as the initial rebiopsy frequency while the other 6 
used 1 year or more. The majority of studies all used similar criteria for inclusion of patients in 
active surveillance, with a combination of PSA, Gleason score, number of positive cores on 
biopsy, percentage of involvement in each core, clinical stage, and/or PSA velocity. Similarly, 
progression criteria were similar, although some studies incorporated PSA and clinical stage to 
measure progression while others used only characteristics derived from prostate biopsy. 
Baseline patient characteristics for all studies were also relatively similar, with mean or median 
ages between 62 and 71, and mean or median PSA below 7.5 ng/mL. However, outcome 
measures were inconsistently reported across studies, as some report median time to biopsy 
while others do not, and some describe risk of progression while others do not. 
 
Study quality 
 Internal validity was measured by the presence or absence of selection bias, measurement 
bias, and confounding. The main risk for selection bias in these studies is that many of the 
studies were single institution studies, which may lead to some self-selection bias as patients 
may have chosen to receive treatment at those institutions. Additionally, recruitment of patients 
was unclear in many studies, although one study specifically mentioned recruiting all eligible 
patients consecutively.13 Some studies had a higher rate of drop out than other studies, and it is 
unclear whether this would have led to differential or non-differential biases. Most of the studies 
had low to moderate risk of measurement bias, and some studies report an in-house pathologist 
that reviewed outside biopsy data. The presence of confounding varied greatly between studies. 
One main source of confounding included progression due to non-biopsy features (including 
PSA level or velocity, and clinical stage), which limits the interpretation of data. In one study, 
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risk of confounding was high as the study was performed in community outpatient clinics, so 
patients could change urologists and the second opinions of those urologists may cause bias 
towards active treatment. 
External validity was evaluated based on whether results from these studies could apply 
to the wider population of men undergoing active surveillance. Many of these studies were 
recruited from a single institution, which led to a rating of “fair” for those studies. One study had 
poor external validity as their criteria for including patients in the active surveillance protocol 
was stricter than others, leading to inclusion of more patients with favorable risk prostate 
cancer.14 One study received a rating of “good” for external validity because patients were 
recruited from 100 medical centers in 17 countries.15 Overall, two studies received an overall 
rating of “good,” two studies received an overall rating of “poor,” while the other 8 studies were 
rating as “fair” (Table 3). 
 
Results of studies 
 Only one study directly assessed risk of progression in relation to timing of repeat biopsy, 
which found that the hazard ratio for progression was 0.40 (95% CI = 0.56-1.58) when the repeat 
biopsy was performed within 6 months. The rest of the studies assessed a mix of probability of 
disease progression, probability of meeting active surveillance criteria at given time points, 
percentage of patients who progressed, rate of intervention in patients, and percentage of patients 
receiving a repeat biopsy. Percentage of patients who underwent repeat biopsy varied from 49% 
to 100% in studies that collected this data. In studies in which repeat biopsy was scheduled to be 
performed between 0 and 1 year, progression-free survival at 5 years was found to be 76%, 72%, 
and 67% in 3 studies. One other study had a treatment-free survival at 5 years of 85%. In those 
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studies where repeat biopsy was scheduled to be performed 1 year or later, progression-free 
survival was found to be 64% and 59% at 5 years in two different studies, and 67.7% at 4 years. 
 
DISCUSSION 
 Overall, there is insufficient evidence regarding frequency of surveillance biopsy in 
prostate cancer patients on active surveillance. In this systematic review, only one article directly 
assessed the risk of disease progression in relation to the timing of the repeat biopsy, which 
found that the hazard ratio for progression was 0.40 (95% CI = 0.56-1.58) when the repeat 
biopsy was performed within 6 months.  
 There are some major limitations with this review. Firstly, many studies did not report a 
median or mean time to biopsy. While there were general guidelines for all studies on when to 
perform a repeat biopsy, patients could receive one earlier in all but 2 studies if they progressed 
due to non-biopsy factors such as rising PSA levels, increasing PSA velocity, or increasing 
clinical stage. This makes it difficult to compare data regarding progression-free survival or rates 
of progression across the intervention and comparison group of performing biopsy before 1 year 
and 1 year or more after start of active surveillance. Secondly, in this review, we were unable to 
use the ideal outcome of survival, and instead used the surrogate end point of disease 
progression. This is not ideal, because this is an intermediate health measure; progression does 
not necessarily mean that a patient will die from prostate cancer, and conversely, not all patients 
who exhibit disease progression will die of prostate cancer.5 Thirdly, only one study out of 12 
assessed the harms of prostate biopsy in terms of pain scores, which is an important 
consideration as the balance of benefits to harms of prostate cancer biopsy frequency should be 
assessed. In addition, follow-up time for the studies are insufficient. According to Schroder et al, 
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an interval of 10 years is too short to evaluate prostate cancer mortality,16 but the longest follow 
up time across all studies in this review is 76 months. 
 Prostate cancer is a disease which affects and kills many men in the United States. At the 
same time, there is a concern that prostate cancer is overdiagnosed in patients, leading to 
unnecessary morbidity and mortality from treatment.4 Active surveillance is a strategy used to 
reduce potential overtreatment of patients, and this review of the literature from 2004-2014 
examines if there are differences in disease progression requiring active treatment in patients that 
receive surveillance biopsy at a frequency of less than 1 year following start of active 
surveillance with patients that receive surveillance biopsy at a frequency of 1 year or more. This 
review demonstrates that insufficient data are present to fully assess this. Future studies that 
directly compare disease progression or survival rates with frequency of biopsy are needed to 
fully assess the optimal schedule for surveillance biopsies.   
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Table 1: PICOTTSS Table 
 Inclusion Exclusion 
Populations Men with localized prostate 
cancer who are undergoing an 
active surveillance protocol 
Men who have previously 
been treated for prostate 
cancer 
Intervention  
 
Rebiopsy frequency 1 year or 
more 
 
Comparison group Rebiopsy frequency less than 
1 year 
 
Outcomes Progression of disease so that 
patient requires active 
treatment (including surgery 
or radiation) 
 
Time for Intervention to 
Work 
Follow-up of at least 12 
months after beginning of 
active surveillance 
 
Time period for relevant 
studies/literature 
Studies published since 2004  Anything prior to 2004 
Setting Studies conducted in Western 
countries 
All other countries 
Study Designs Longitudinal studies  All other designs 
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Figure 1: Flow Diagram of Search and Selection of Articles for Review  
 
 
 
 
 
 
  
19 
 
Table 2: Studies of patients on active surveillance comparing different frequencies of surveillance biopsy 
 
Author, 
Year 
(Reference) 
Sample 
Size 
Participant 
Characteristics 
Active Surveillance 
Criteria 
Progression Criteria Frequency of 
Rebiopsy 
Study Results 
Adamy 
201117 
238  Median age: 64 
years  
 Median time to 
biopsy: 4.7 mos 
 Median PSA: 4.1 
ng/mL 
 Patients 
recruited 
between 1993-
2009 
 PSA < 10 ng/mL 
 Gleason < 7 
 ≤ 3 positive biopsy 
cores 
 Clinical stage ≤ T2a 
 Tumor in less than 50% 
of 1 biopsy core 
 PSA ≥ 10 ng/mL 
(although not 
included in modified 
criteria) 
 Gleason ≥ 7 
 >3 positive cores 
 Clinical stage > T2a 
 Tumor in greater 
than 50% of 1 biopsy 
core 
 Confirmatory 
rebiopsy  
within 6 mos 
 12-18 mos 
following AS, 
then 2-3 years 
following 
 When clinical 
exam changed 
or PSA 
increased 
 32/238 found to progress on 
modified criteria (which does 
not include PSA levels) 
 2 and 5 year probability for 
meeting modified active 
surveillance criteria of 91% 
and 76% respectively 
 63% of patients receive 
confirmatory biopsy within 6 
mos, 58% of those without 
cancer 
 Progression when biopsy 2 is 
within 6 months of biopsy 1 
(HR = 0.4, 95% CI = 0.56-1.58) 
Al Otaibi 
200812 
186  Median age: 67 
years 
 Patients 
recruited from 
1987 and 2006 
 
 
 Not specified  T ≥ cT2b 
 ≥3 positive cores 
 Tumor in greater 
than 50% of 1 biopsy 
core 
 Gleason pattern of 4 
or greater 
 12 months 
following AS 
 When clinical 
exam changed 
or PSA 
increased 
(checked every 
3-6 months) 
 
 49% patients were rebiopsied 
 36% progressed on rebiopsy 
 First repeat biopsy positive in 
52% of patients 
 31% received definitive 
treatment 
 Probability of disease 
progression: 
 12 mos: 8.7 
 24 mos: 23.4 
 60 mos: 35.8 
 Median time to treatment: 44 
months 
 Median follow-up: 76 mos 
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Bul 201215 2494  Median age: 65.8 
years 
 Median time to 
first biopsy: 1.1 
years 
 Median PSA: 5.6 
ng/mL 
 Patients from 
PRIAS study 
starting from 
2006 
 
 PSA ≤ 10 ng/mL 
 PSA density < 0.2 ng/mL 
 <3 positive biopsy cores 
 Gleason ≤ 6 
 Clinical stage T1/T2 
 
 > 2 positive cores 
 Gleason > 6 
 PSA doubling by < 3 
years 
 1, 4, 7 years 
 Yearly if PSA 
doubles 
between 3-10 
years 
 PSA every 3 
mos for first 2 
years, then 
every 6 mos 
 Repeat biopsy in 1480 men 
 Out of those rebiopsied, 28% 
reclassified (does not include 
PSA doubling) 
 Median time to active therapy 
1.2 years 
 21.1% underwent active 
therapy 
 387/2494 (15.5%) received 
treatment due to biopsy 
progression 
 Active treatment free survival: 
 2 yr: 77.3% 
 4 yr: 67.7% 
Iremashvili 
201318 
161  Median age: 62 
years 
 Media PSA: 4.9 
ng/mL 
 All patients 
recruited from 
University of 
Miami from 1994 
to 2001 
 Gleason ≤ 6 
 ≤ 2 positive cores 
 ≤ 20% involvement of 
any core 
 Clinical stage T1-T2a  
 Gleason 4/5 cancer 
 > 2 positive cores 
 >20% involvement of 
any core 
 Within 1 year 
of diagnosis, 
and then 1-2 
years 
following 
 PSA/DRE 
checked every 
3-4 months 
 100% of patients underwent 
at least 2 surveillance biopsies 
 First surveillance biopsy did 
not contain cancer in more 
than 50% of patients 
 28.6% of patients progressed 
 Median follow-up: 3.6 years 
 
King 201313 
 
67  Mean age: 63.9 
years  
 Mean PSA: 5.9 
ng.mL 
 Patients 
recruited from 
University of 
Wisconsin 2007-
2011 
 Gleason < 7 
 PSA < 10 ng/mL 
 PSA density < 0.15 
 < 3 positive biopsy 
cores 
 < 50% involvement of 
any core 
 Gleason ≥ 7 
 PSA ≥ 10ng/mL 
 PSA density ≥ 0.15 
 ≥ 3 positive biopsy 
cores 
 ≥ 50% involvement 
of any core 
Within 6 
months 
 Average time to rebiopsy: 2.7 
mos 
 78% underwent rebiopsy 
 56% demonstrated no 
evidence of CaP on rebiopsy 
 17% exceeded AS criteria 
(offered treatment) 
 7.7% received treatment 
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Klotz 
201219 
 
450  Median age: 70.3 
 85% of patients 
had PSA ≤ 10 
 12% had PSA 
between 10 and 
15 
 Patients 
recruited starting 
from 1995 
 
 
 Between 1995-1999: 
 Gleason ≤ 6 
 PSA ≤ 10 for patients 
< 70 
 For patients > 70, 
PSA ≤ 15, Gleason ≤ 
3+4 
 
 After 2000, limited to 
favorable risk patients 
only 
 PSA doubling time 
<3 years (2 years 
used for first 4 years 
of study) 
 Gleason score ≥ 4+3 
 “Unequivocal clinical 
progression” 
 Nodules 
 6-12 months 
after starting 
AS, 3-4 years 
after 
 PSA every 3 
months for 2 
years, then 
every 6 
months if 
stable 
 48% progression due to PSA 
doubling time 
 26% progression due to 
Gleason upgrading 
 Intervention in 30% patients 
 Likelihood of remaining on 
surveillance: 84%, 72%, 62% 
for 2, 5, and 10 years 
 Median follow-up time 6.8 
years 
 5 and 10 year cause specific 
survival of 99.7% and 97.2%  
Kravchick 
201120 
48  Mean age: 68.4 
years 
 Mean PSA: 7.4 
ng/mL 
 Patients 
recruited from 
community 
outpatient clinics 
of 2 health 
insurance 
companies from 
1998-2006 
 
 PSA ≤ 10 ng/mL 
 Gleason ≤ 6 
 Clinical stage T1a/T1c 
 < 3 positive biopsy 
cores 
 < 30% involvement of 
any core 
 
Increases in Gleason 
score or number of 
positive cores 
considered indications 
for active treatment 
 18 months 
after starting 
AS or changes 
in PSA or DRE 
measured 
every 3 
months 
 28/48 patients underwent 
rebiopsy 
 41.7% underwent active 
treatment, but half of them 
met medical criteria 
 Mean follow-up: 81.1 mos 
 Pain scores statistically 
significantly higher in those 
who underwent 3 or more 
biopsies 
Patel 
200421 
88  Mean age: 65.3 
years 
 Mean PSA: 5.9 
ng/mL 
 Patients 
recruited from 
Baylor College of 
Medicine or 
Memorial Sloan 
 Gleason ≤ 7 
 Clinical stage T1/T2 
 
 
Point system with 
Gleason score 
increase, PSA velocity 
increase, DRE/TRUS 
indications of lesions, 
and number of cores, 
needing 3 points to 
progress  
 6 months after 
starting active 
surveillance 
 Or changes in 
DRE/TRUS/ 
PSA indicating 
progression 
 25% of patients progress 
 Actuarial 5 and 10 year 
progression-free survival: 67% 
and 55% 
 31/88 patients treated 
 Repeat biopsy median of 8 
months after diagnosis, 16% 
progress 
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Kettering Cancer 
Center between 
1984 and 2001 
 Median time to progression 
(in cases that progressed): 45 
months 
 Positive rebiopsy significantly 
associated with progression (p 
= 0.004) 
 Median follow-up: 44 months 
 
Porten 
201122 
377  Mean age: 61.9 
 Median PSA: 5.74 
ng/mL 
 Patients from 
University of 
California at San 
Francisco 
Urologic 
Oncology 
Database 
included 
between 1998 
and 2009 
 
 PSA < 10 ng/mL 
 Gleason ≤ 6 with no 
Gleason 4 or 5 
component 
 Cancer involvement of 
<33% of biopsy cores 
 Clinical stage: T1/T2a 
 Also included men who 
wished to undergo AS 
outside these criteria 
Increase in primary or 
secondary Gleason 
score 
 12-24 months 
after AS 
 Repeat PSA 
and DRE every 
3 months 
 Median time between 
biopsies from 12-16 months 
 54% of men had 2 or more 
repeat biopsies 
 34% had increase in Gleason 
grade 
 105/377 experienced Gleason 
upgrade within 30 months of 
initial diagnosis 
 59% of those underwent 
definitive treatment (76/377 
total) 
 Treatment-free survival rates 
at 5 years after diagnosis 40% 
for those who upgraded and 
80% for those with no 
upgrade 
 Mean follow-up time: 54 
months after first repeat 
biopsy 
 Another 37/377 chose to 
undergo treatment despite no 
change in Gleason score 
Soloway 
200823 
99  Median age: 67 
 Median PSA: 5.77 
 Gleason score ≤ 6 
 PSA ≤ 15 ng/mL 
 Clinical stage ≤ T2 
 Increase in PSA 
velocity of PSA 
doubling time 
 6-12 months 
after AS, then 
yearly 
 65% of patients had initial 
repeat biopsy 
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 Patients followed 
from 1992-2007 
  Tumor in less than 50% 
of two biopsy cores 
 Excluded men ≥ 80 
years of age 
 > 12 months follow up 
 Gleason ≥ 7 
 Tumor volume 
increase 
 Stage progression 
 Repeat PSA 
and DRE every 
3 months 
 8/99 (8%) underwent 
treatment 
 5-year probability of 
treatment-free survival 85% 
 Median follow-up: 38 months 
 
Thomsen 
201324 
167  Median age: 65 
years 
 Median PSA: 6.5 
 Median time to 
first biopsy: 12.7 
months 
 Patients included 
from 2002 to 
2011 
 
 
 
 PSA ≤ 10 ng/mL 
 Gleason ≤ 6 
 Clinical stage T1-2a 
 ≤ 3 positive biopsy 
cores 
 Tumor in less than 50% 
of biopsy cores 
 Possible progression 
(intermediate risk): 
 PSA double time 
3-5 years 
 Increase in 
Gleason score to 
3+4 
 cT2b 
 Recommend 
treatment (high-
risk): 
 PSA doubling 
time < 3 years 
 Increase in 
Gleason score to 
≥4+3, or > 3 
positive cores 
 ≥cT2c 
 Within 15 
months 
following AS 
 Repeat PSA 
and DRE every 
3 months 
 Median follow-up: 3.4 years 
 86% of subjects received 
rebiopsy 
 20% progressed on re-biopsy 
alone 
 82% of these within first 2 
years 
 22% reclassified as 
intermediate risk 
 17% reclassified as high-risk 
Tosoian 
201114 
769  Median age: 66 
years 
 Median PSA: 5.0 
ng/mL in treated 
group, 4.7 ng/mL 
in not treated 
group 
 Mean time to 
first biopsy: 1.3 
years 
 Gleason ≤ 6 
 ≤ 2 positive biopsy 
cores 
 Clinical stage ≤ T1c 
 Tumor in less than 50% 
of 1 biopsy core 
 PSA density < 0.15 
ng/mL 
 Gleason > 6 
 > 2 positive biopsy 
cores 
 Tumor in more than 
50% of 1 biopsy core 
 
 12 months 
following AS 
 “Semiannual” 
PSA and DRE 
exams 
 Median follow-up: 2.7 years 
 Compliance with annual 
surveillance biopsies was 92% 
for first biopsy 
 Median survival free of 
intervention: 6.5 years 
 33.2% of men underwent 
intervention at median of 2.2 
years 
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 Time between 
subsequent 
biopsies: 1.1 
years 
 Patients 
recruited all from 
Johns Hopkins 
since 1995 
 73.7% of all men who 
underwent intervention did so 
due to biopsy related disease 
reclassification 
 Proportion of men 
intervention-free: 
 2 years: 81% 
 5 years: 59% 
 10 years: 41% 
 
 
Table 2: Risk of bias in studies 
 
Author, Year 
(Reference) 
Internal Validity External Validity Overall 
Rating 
Overall Conclusions 
Selection Bias Measurement 
Bias 
Confounding 
Adamy 
201117 
High 
 
Unclear how 
patients were 
recruited, 
relatively few 
lost to follow up. 
Low-Moderate 
 
Most of the 
measures are 
standardized, 
unlikely that 
clinical stage or 
pathology 
differs   
Low – Moderate 
 
Other factors such 
as clinical stage 
could result in 
progression, not 
just biopsy results. 
PSA levels 
excluded. 
Fair 
 
Unclear how this 
patient group 
compares to 
general 
population 
Fair  The median time to biopsy in this 
cohort is 4.7 mos, however the hazard 
ratio for progression is not significant. 
 About 13% of patients progressed, 
however it is unclear when the 
progression occurred.  
Al Otaibi 
200812 
High 
 
Recruitment of 
patients not 
described 
Low 
 
1 out of 2 
pathologists 
reviewed 
biopsy data 
Moderate 
 
Other factors such 
as clinical stage 
could result in 
progression, not 
just biopsy results. 
Fair 
 
10% of patients 
have baseline 
PSA > 10 ng/mL 
Fair  Results are difficult to interpret for 
purposes of this review, as less than 
half of patients received rebiopsy 
 Progression criteria includes clinical 
stage, not just biopsy 
 No analysis for timing of biopsy 
relating to risk of progression 
 Long follow up time 
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 Disease progression appears most 
likely in the first 2 years 
Bul 201215 Low 
 
 PRIAS study 
(100 medical 
centers in 17 
countries) 
 Baseline 
characteristics 
similar 
 Low drop out 
rate (1.7%) 
Low-Moderate 
 
Internet-based 
tool (Unclear if 
abstractors are 
blinded, and 
how many 
there are) 
 
 
Low Good 
 
Large study 
across 17 
countries and 
100 medical 
centers 
Good  Well done study, no data directly 
showing frequency of rebiopsy with 
disease progression 
 Median time to biopsy is 1.2 years, 
59% of patients receive a repeat biopsy 
 Active treatment free survival at 2 
years is 77.3% and 67.7% 
 This study started recruited patients 
more recently than most other studies 
in this review (starting in 2006) 
Iremashvili 
201318 
Moderate 
 
Possible self-
selection bias  
due to 
recruitment at 
single institution 
Low 
 
 Outside 
biopsy slides 
reviewed by 
institutional 
genitourinary 
pathologist 
 Clinical stage 
by attending 
urologist 
Low  
 
Progression was 
only noted due to 
biopsy features 
Fair 
 
All patients 
recruited at 
single institution, 
unclear how this 
compares to 
general 
population 
Good  Used 3 models (diagnostic biopsy, first 
surveillance biopsy, and combination 
of the two) to analyze risks of 
progression 
 However, time to surveillance biopsy 
was not included 
King 201313 
 
Moderate 
 
 Recruitment of 
patients were 
consecutive 
 Single 
institution 
 Relatively high 
dropout rate, 
Low 
 
 Outside 
biopsy slides 
reviewed by 
institutional 
genitourinary 
pathologist 
Moderate-High 
 
Low number of 
men with prostate 
cancer choosing 
active 
surveillance, these 
men may more 
less inclined to 
Fair 
 
All patients 
recruited at 
single institution, 
lower number of 
prostate cancer 
patients choosing 
Fair  Rebiopsy within 6 months, high rate of 
rebiopsy 
 Many patients demonstrated lack of 
prostate cancer on rebiopsy (56%) 
 7.7% of patients treated 
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but likely non-
differential 
 22/67 (22%) 
dropped out 
due to lack of 
desire for 
second biopsy 
 Recording of 
data unlikely 
to result in 
measurement 
differences 
 Time to 
rebiopsy 
limited to 6 
months 
 
undergo 
treatment 
active 
surveillance 
Klotz 201219 
 
Moderate-High 
 
Unclear how 
patients 
recruited 
Low  
 
 Recording of 
data unlikely 
to result in 
measurement 
differences 
 
Moderate 
 
Other factors such 
as clinical stage or 
PSA kinetics could 
result in 
progression, not 
just biopsy results. 
Fair 
 
All patients 
recruited at 
single institution, 
lower number of 
prostate cancer 
patients choosing 
active 
surveillance 
Fair  Goal of study is to assess feasibility of 
observation with selective delayed 
intervention in prostate cancer 
patients (different goal than this 
review) 
 Triggers for progression are PSA 
kinetics and biopsy data 
 High follow-up time 
Kravchick 
201120 
Moderate-High 
 
Enrollment rate 
of only 17.8%  
High 
 
Criteria 
changed in 
2004, prior to 
this date, 
protocol for 
repeat biopsy 
was not 
present 
High 
 
Study was done in 
community 
outpatient clinics, 
patients change 
urologists and 
second opinions 
may cause bias 
towards active 
treatment 
Fair 
 
Only included 
patients between 
60-75 years of 
age, however 
patients 
recruited from 
community 
outpatient clinics 
(likely more 
representative of 
overall 
population) 
Poor  Unclear when patients underwent 
surveillance biopsy (no median or 
mean time given, since they could 
receive one at 18 months or from PSA 
or clinical progression), makes results 
difficult to interpret in context of this 
review 
 Pain scores higher in patients who 
underwent 3 or more biopsies 
 Low sample size 
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Patel 200421 Moderate-High 
 
Unclear how 
patients 
recruited 
Moderate 
 
PSA velocity 
calculated from 
3 recorded 
values in a 1 
year period 
Moderate-High 
 
Excluded patients 
with significant 
comorbidities, a 
population which 
frequently 
undergoes active 
surveillance 
Fair 
 
Patients 
recruited at two 
well-known 
cancer 
institutions, 
unclear how this 
compares to 
general 
population  
Poor  This study started recruited patients 
more less recently than most other 
studies in this review (starting in 1984) 
 Relatively small sample size 
 Repeat biopsy median of 8 months 
after diagnosis, 16% progress 
 
Porten 
201122 
Low-Moderate 
 
 All patients 
from single 
institution, 
possible self-
selection bias 
 Only 3% lost to 
follow up 
 
Low 
 
Biopsies all 
underwent 
slide review by 
in-house 
pathologist 
Low  
 
Progression was 
only noted if 
Gleason score was 
upgraded 
Fair 
 
All patients 
recruited at 
single institution, 
unclear how this 
compares to 
general 
population  
Good  Large sample size 
 Only progressed if Gleason score was 
upgraded 
 Unclear how many patients only had 1 
repeat biopsy 
 Unsure of progression free survival 
Soloway 
200823 
Moderate 
 
 Unclear how 
patients were 
recruited 
 Baseline 
characteristics 
appear similar 
for overall and 
treated groups 
 7/99 lost to 
follow up 
Moderate 
 
Database 
designed for 
entering of 
relevant clinical 
and pathologic 
data 
Moderate 
 
Other factors such 
as clinical stage or 
PSA levels could 
result in 
progression, not 
just biopsy results 
Fair 
 
All patients 
recruited at 
single institution, 
unclear how this 
compares to 
general 
population 
Fair  Sample size is moderate 
 Unclear when the median biopsy time 
is 
 Progression criteria includes clinical 
stage and PSA, not just biopsy 
 No analysis for timing of biopsy 
relating to risk of progression 
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Thomsen 
201324 
Low-Moderate 
 
All patients from 
single institution, 
possible self-
selection bias 
Low 
 
All biopsies re-
evaluated by in 
house 
uropathologist 
Moderate 
 
Other factors such 
as clinical stage 
could result in 
progression, not 
just biopsy results 
Fair 
 
6% of patients 
with Gleason 
score of 7 
Fair  Relatively high rate of rebiopsy, mean 
time until first surveillance biopsy 
listed 
 Most of those who progressed on 
rebiopsy did so within first two years 
 Unfortunately no data directly 
comparing biopsy time to progression 
 Sample size is moderate 
Tosoian 
201114 
Moderate 
 
 Patients 
recruited all 
from Johns 
Hopkins  
 Baseline 
characteristics 
between 
treated and 
untreated 
mostly similar, 
although mean 
and median 
year of 
diagnosis in 
those not 
treated was 3 
years later 
 12% dropped 
out 
Low-Moderate 
 
Most of the 
measures are 
standardized, 
unlikely that 
clinical stage or 
pathology 
differs   
Low Poor 
 
These patients 
are very-low risk, 
with stricter 
enrollment 
criteria, and all 
recruited from 
Johns Hopkins, 
which may be 
different from 
the general 
population 
Fair  Comparing this to other studies in this 
review is difficult, because patients 
recruited are all very-low risk with 
stricter enrollment criteria 
 Pros are that mean time until first 
surveillance biopsy is listed, as well as 
compliance 
 Sample size is large  
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Comparison of Patient versus Physician Reporting of Comorbidities, Results 
from a Population-Based Cohort of Prostate Cancer Patients 
 
 
ABSTRACT 
Purpose: Baseline patient comorbidities influence treatment decision making and survival 
outcomes for prostate cancer. Although studies now commonly collect comorbidity information, 
some via patient report and others through physician report, the agreement between these two 
information sources is unknown. This study aims to compare patient vs. physician-reported 
comorbidity in a recently accrued population-based cohort of patients with localized prostate 
cancer. 
Methods: Patients with non-metastatic prostate cancer diagnosed from 2011-13 were recruited 
via collaboration with the North Carolina Central Cancer Registry. In a sample of 811 patients, 
phone survey and medical record abstraction for presence/absence of common comorbidities was 
conducted. We calculated percent agreement and its kappa statistic between patient and 
physician-report for each condition. We performed subgroup analysis to examine differences in 
agreement adjusting for age, race, marital status, education level, income, and risk group. 
Logistic regression was used to examine covariates associated with agreement. 
Results: Overall, agreement in 20 comorbidities was moderate. For some conditions (myocardial 
infarction, cerebrovascular disease, diabetes, HIV/AIDS, and hypertension), agreement was high 
(kappa > 0.62), but for all other conditions agreement was low to moderate. In subgroup 
analysis, non-Caucasians have lower patient- vs. physician-report agreement for chronic 
obstructive pulmonary disease, liver disease, other cancers, and coronary artery disease; but the 
opposite was true for congestive heart failure, clotting disorders, and inflammatory bowel 
disease. The findings based on education level were similarly mixed. On multivariable analysis, 
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older age was significantly associated with lower overall agreement for myocardial infarction, 
cerebrovascular disease, kidney disease, coronary artery disease, and arrhythmia. 
Conclusion: Agreement between patient and physician reporting of common comorbidities in 
newly-diagnosed prostate cancer patients is moderate. In research studies, whether physician 
reporting, patient reporting, or both should be used to inform treatment decision making and 
predict survival outcomes is unclear. 
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INTRODUCTION 
 Prostate cancer treatment decision making and survival outcomes are greatly affected by 
patient baseline comorbid conditions.1,2 Because the median age of diagnosis of prostate cancer 
in the United States is 67 years,3 many patients have other medical conditions concomitantly, 
such as diabetes, hypertension, cardiovascular disease, and cerebrovascular disease.4,5 Radical 
prostatectomy (RP) is a more likely treatment given to younger patients with fewer 
comorbidities, while radiation therapy (RT) and conservative management (hormone therapy or 
no treatment) are more likely given to older patients and those with more comorbidities.3,6-8 
There are additional reports demonstrating that patients with fewer comorbidities are more likely 
to travel long distances to receive treatment, such as proton therapy, at large volume academic 
centers.9 
There are a number of treatment options for patients with localized prostate cancer, and 
the comparative effectiveness of patient outcomes among these options is one of the highest 
priority research areas according to the Institute of Medicine.10 Because a patient’s comorbid 
conditions heavily influence treatment selection and directly impact survival and also health-
related quality of life outcomes,1,2,11 observational comparative effectiveness research studies 
must account for these conditions. A central methodological issue is whether to collect 
comorbidity data using medical record abstraction or patient report in order to maximize data 
quality while minimizing cost of data collection. Medical record collection and abstraction 
depends on the scrupulousness of the documenting provider, requires an abstractor with 
sufficient medical training, and is more costly to perform.12 On the other hand, patient report 
relies on each individual patient accurately knowing his medical history – which may be 
dependent in part on the health literacy of the patient.  
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The purpose of this study is to compare patient- vs. physician-reported comorbidity in a 
population-based cohort of patients with newly diagnosed prostate cancer. We quantify the level 
of agreement between these two sources on a list of most common comorbid conditions in these 
men, and assess factors associated with agreement. Given that low socioeconomic status may be 
associated with poor health literacy,13,14 we hypothesized that patients who were non-white and 
those with lower educational attainment would have lower agreement in patient-report vs. 
physician-report. 
 
METHODS 
Data collection  
The North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study 
(NC ProCESS) is a prospective, population-based cohort of newly-diagnosed localized prostate 
cancer patients enrolled throughout North Carolina in collaboration with the Rapid Case 
Ascertainment (RCA) system of the North Carolina Central Cancer Registry. RCA is a research 
infrastructure with the state Cancer Registry which proactively identified newly-diagnosed 
prostate cancer patients from all 100 counties in North Carolina from 2011 to 2013. Names of 
patients, pathology and diagnostic information, as well as their physician’s names and addresses 
were sent to RCA staff by tumor registrars at local hospitals on a weekly basis. These patients 
were then approached by NC ProCESS staff for study participation. All patients were enrolled 
before treatment. Participating patients were followed prospectively to collect data on patient-
reported outcomes and from medical records.  
Outcome Measures 
This study included 881 patients enrolled in NC ProCESS with data collected on the 
following 20 common comorbid conditions: myocardial infarction, congestive heart failure, 
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peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, 
peptic ulcer disease, liver disease, diabetes, kidney disease, other cancers, human 
immunodeficiency virus / acquired immune deficiency syndrome, coronary artery disease, 
arrhythmia, clotting disorders, hypertension, hyperlipidemia, inflammatory bowel disease, 
asthma, anemia and other blood disorders, and arthritis. These conditions are included in the 
most commonly used comorbidity indices used in cancer research, including the Charlson 
Comorbidity Index,15-17 Adult Comorbidity Evaluation Index (ACE-27),18 Index of Co-Existent 
Diseases (ICED),16,17 and Kaplan-Feinstein Comorbidity Index.17,19,20 The conditions were 
assessed two ways – by patient-report via phone survey (with the question: “have you ever been 
told by a doctor or other health professional that you have [comorbid condition]?”) and by 
medical record abstraction – at the time of study enrollment, which was always before treatment. 
Medical records were collected from the patient’s primary care physician and prostate-cancer 
providers, including urologist and radiation oncologist, and abstracted for presence of these 
comorbid conditions.  
Statistical Analysis 
 We describe the presence of each condition based on patient report, medical record 
abstraction, both, or neither; kappa statistics were used to quantify the level of agreement 
between patient-report and medical records. Landis and Koch (1977) thresholds were used to 
classify agreement levels as poor/slight (<0.20), fair (≥0.20 – <0.40), moderate (≥0.40 – <0.60), 
substantial (≥0.60 – <0.80), or almost perfect (≥0.80).21 We performed subgroup analyses to 
determine if kappa varied by age, race, marital status, education level, income, or cancer 
aggressiveness (as defined by prostate cancer risk group).22 We then performed logistic 
regression to assess covariates associated with overall agreement between patient-report and 
medical records in each condition. The subgroup and multivariable analyses inform our 
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understanding of whether certain prostate cancer patient subgroups have higher or lower 
agreement in terms of presence of comorbid conditions from the two data sources. All statistical 
analyses were performed using SAS 9.4 (SAS Institute, Cary, NC).  
 
RESULTS 
Baseline cohort characteristics are shown in Table 1. Median age was 65 years. This 
cohort is diverse with 28% non-Caucasian participants, 32% with high school education or less, 
and 37% with household income ≤ $40,000. Overall, 28% of patients had a family history of 
prostate cancer. 
 Table 2 shows the frequency of patient and physician reporting of each comorbid 
condition, the level of agreement, and kappa statistics. Agreement was poor or fair (kappa = 
0.14-0.39) for peripheral vascular disease, peptic ulcer disease, kidney disease, other cancers, 
coronary artery disease, arrhythmia, hyperlipidemia, asthma, anemia and other blood disorders, 
and arthritis; moderate (kappa = 0.43-0.56) for congestive heart failure, chronic obstructive 
pulmonary disease, liver disease, clotting disorders, and inflammatory bowel disease; and 
substantial or almost perfect (kappa = 0.62-1.00) for myocardial infarction, cerebrovascular 
disease, diabetes, human immunodeficiency virus or acquired immune deficiency syndrome, and 
hypertension. When there was disagreement, both scenarios – a) medical records indicating 
condition but not reported by patients, and b) patient indicating presence of condition but not 
indicated in medical records – were observed. For cerebrovascular disease, chronic obstructive 
pulmonary disease, diabetes, coronary artery disease, and hypertension, medical records were 
more likely to report the condition than patients (scenario a); while for myocardial infarction, 
congestive heart failure, peptic ulcer disease, kidney disease, other cancers, arrhythmia, clotting 
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disorders, hyperlipidemia, asthma, anemia and other blood disorders, and arthritis, patients were 
more likely to indicate the condition (scenario b). 
 Subgroup analysis for kappa based on age, race, marital status, education, income, and 
prostate cancer risk groups for each comorbid condition is shown in Table 3. Kappa which 
differed by 0.20 or more among subgroups was highlighted, and this difference was observed in 
15 conditions. Specifically, kappa differed by patient race in 7 conditions: Caucasian patients 
had higher kappa in chronic obstructive pulmonary disease, liver disease, cancers other than 
prostate, and coronary artery disease; while non-Caucasians had higher kappa in congestive heart 
failure, clotting disorders, and inflammatory bowel disease. Kappa also differed by education in 
4 conditions: patients with a high school education or less had higher kappa in kidney disease, 
clotting disorders, and anemia and other blood disorders; while those with more than a high 
school education had a higher kappa in inflammatory bowel disease. 
 In multivariable logistic regression, older age was associated with lower overall 
agreement in multiple conditions: older than 70 years compared to less than 60 years was 
associated with lower overall agreement for myocardial infarction (OR = 0.31, 95% CI = 0.12-
0.80), cerebrovascular disease (OR = 0.10, 95% CI = 0.01-0.78), kidney disease (OR = 0.18, 
95% CI = 0.06-0.52), coronary artery disease (OR = 0.37, 95% CI = 0.20-0.67), and arrhythmia 
(OR = 0.44, 95% CI = 0.25-0.79); age between 60 and 69 years compared to less than 60 years 
was associated with lower overall agreement for cerebrovascular disease (OR = 0.11, 95% CI = 
0.01-0.85), kidney disease (OR = 0.33, 95% CI = 0.12-0.91), and coronary artery disease (OR = 
0.55, 95% CI = 0.31-0.96). Nonwhite race was associated with lower overall agreement for 
kidney disease (OR = 0.21, 95% CI = 0.10-0.43). A high school education or less compared to 
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more education was associated with higher overall agreement for anemia and other blood 
disorders (OR = 2.57, 95% CI = 1.24-5.33).  
Across the 20 comorbid conditions assessed in this study, the number of conditions for 
which there was disagreement between the patient and the physician for each individual patient 
is shown in Table 5. Patients and physicians agreed on all conditions in 20% of cases. There 
were 1 or more disagreed conditions in 80% of cases, 2 or more in 48% of cases, 3 or more in 
26% of cases, 4 or more in 13% of cases, and 5 or more in 6% of cases. 
 
DISCUSSION 
 In this study of 881 prostate cancer patients from a diverse, population-based cohort, we 
examined the agreement between patient-report vs. physician-documentation (via medical record 
abstraction) in 20 comorbid medical conditions which are commonly included in comorbidity 
indices used in cancer research. We found that for some conditions (myocardial infarction, 
cerebrovascular disease, diabetes, HIV/AIDS, and hypertension), agreement was high, but for all 
other conditions agreement was low to moderate. In subgroup analysis, our hypothesis that non-
Caucasians have lower patient- vs. physician-report agreement was demonstrated to be correct 
for chronic obstructive pulmonary disease, liver disease, other cancers, and coronary artery 
disease; but we found the opposite to be true for congestive heart failure, clotting disorders, and 
inflammatory bowel disease. The findings based on educational attainment were similarly mixed. 
On multivariable analysis, older age was significantly associated with lower overall agreement 
for myocardial infarction, cerebrovascular disease, kidney disease, coronary artery disease, and 
arrhythmia. 
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 Accurate assessment of comorbidities is important because prostate cancer treatment 
decision making is directly affected by a patient’s baseline comorbidity status.1,2 In a 2006 
population-based study from the Eindhoven Cancer Registry, patients with no comorbidities as 
scored using the Charlson Comorbidity Index underwent prostatectomy much more commonly 
than those with two or more comorbid conditions.23 Similar practice patterns are seen in the US, 
where younger and healthier patients commonly receive prostatectomy, while older and those 
with more comorbid conditions receive radiation therapy or conservative management.20 
Comparative effectiveness research (CER) for localized prostate cancer treatment options 
(prostatectomy, radiation, active surveillance) is one of the highest priority research areas,10 and 
because of the heavy patient selection into different treatment groups, must accurate account for 
a patient’s comorbid conditions in order to reach valid conclusions. Because a patient’s comorbid 
conditions directly impact survival2 and health-related quality of life,11 two of the most important 
outcomes in comparing localized prostate cancer treatment options,10 a better understanding of 
how to assess this information addresses one of the most important methodologic issues in CER 
and will help optimize quality of data versus cost of data collection.  
 Our study is novel because to our knowledge, there have been no prior studies conducted 
directly comparing patient- and physician- report of comorbidities specifically in prostate cancer 
patients. Both sources of information are used in different prostate cancer studies to account for 
comorbidities.2,7,23-32 In our literature search, we found a validation analysis from the Prostate 
Cancer Outcomes Study showing that agreement between medical record review and patient 
survey exceed 90% in diabetes, myocardial infarction, inflammatory bowel disease, chronic lung 
disease, heart failure, stroke, bleeding from stomach ulcers, and liver disease; while agreement 
was lower for arthritis (68%) and hypertension (78%),24 which are comparable to our results. Our 
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study differs from this one in that we also assessed kappa statistics to determine if agreement 
seen is better than chance agreement alone. We also found another study conducted almost 20 
years ago by Katz et al. in a sample of 170 hospitalized patients.12 For conditions studied which 
overlap with our study, kappa values are similar (within 0.20) for myocardial infarction, 
congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive 
pulmonary disease, and peptic ulcer disease, while they differ by more than 0.20 for diabetes, 
kidney disease, and other cancers.12 However, the Katz study did not specifically include cancer 
patients, and did not examine whether kappa differed by patient subgroups.12 Another study 
published in 1989 of 338 patients with chronic lymphocytic leukemia found kappa values for 
rheumatoid arthritis and arthritis otherwise unspecified to be 0.08 and 0.27, respectively.33  Our 
overall results are fairly consistent with these three prior studies. 
Results from this study provide important information for CER investigators, and calls 
for further methodologic work to examine how to best account for patient comorbidities in 
comparative research. Importantly, we found low to moderate agreement in some important 
comorbid conditions, including congestive heart failure, peripheral vascular disease, chronic 
obstructive pulmonary disease, coronary artery disease, arrhythmia, and asthma. Further, we 
found lower agreement in several cardiovascular conditions especially in older patients, the 
patient subgroup most likely to be affected by these conditions.20 In this study, we obtained and 
abstracted medical records from the primary care physician and cancer specialists – because we 
felt these were the most relevant physicians for a prostate cancer patient, and that the primary 
care physician would be expected to know and document all of a patient’s medical conditions. 
Doing so, we found that patient-report indicated the presence of 11 conditions more often than 
medical records; i.e. physicians “missed” these comorbid conditions. It is possible that obtaining 
39 
 
records from additional sources would increase agreement with patient-report, but it is also 
possible that some patients may report presence of certain medical conditions incorrectly. As NC 
ProCESS obtains longer-term follow-up in these patients, we will be able to assess whether 
patient-report, medical records, or both best predict patient survival and health-related quality of 
life outcomes.  
Patient reported outcomes research suggests that there is discordance between patient and 
providers in assessing symptoms, side effects, and quality of life.34-38 Patients tend to report 
symptoms earlier and more frequently than do physicians.35 In terms of quality of life 
assessment, subjective domain measures result in less agreement between patients and clinicians 
than the more objective domain measures.37 Thematically, this fits in with results from our study, 
in that there are discrepancies between patient and physician reporting of comorbidities, and that 
patient reporting of comorbidities demonstrates presence of comorbidity more often than 
physician report.  
Data collection from physician sources comes from electronic medical records or 
traditional paper records. Gathering data from paper charts may be more difficult and costlier to 
perform, as records typically need to be scanned or may be hard to read. However, the use of 
electronic medical records by office-based physicians has risen in the United States in the past 
decade.39 The implementation of internet-based personal health records (PHRs) will allow 
patients to access, add content, and share their medical records.40,41 While this may be limited by 
health literacy,42 future PHR usage may result in more accurate information regarding 
comorbidities in the future, as patients will be able to more easily inform their providers of 
comorbidities the provider may have missed and vice versa.  
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 This study contains multiple methodological strengths. The NC ProCESS cohort is large 
and population-based, and the rich diversity of enrolled patients allowed for subgroup analyses to 
examine agreement by age, race, educational attainment and other factors. Enrollment of patients 
from the community setting also provides information that is reflective and generalizable to “real 
world” prostate cancer patients and medical care. In addition, patient-reported comorbidity 
information and medical records were both obtained prior to prostate cancer treatment, which 
avoids potential confounding from conditions developed due to treatment and its complications. 
On the other hand, our description of a meaningful difference in kappa among subgroups 
(difference of ≥ 0.2) is arbitrary. In our literature search, we were unable to find any existing data 
on what constitutes a meaningful difference in kappa values. As such, we defined a significant 
difference to be greater than 0.20 based on the 1977 Landis and Koch kappa classifications,21 but 
provide the actual values in Table 3 to allow the reader to make his/her own conclusions. 
 In conclusion, in a population-based cohort of patients with newly-diagnosed prostate 
cancer, agreement between patient and physician reporting of common comorbid conditions 
ranged from low to high. In 4 conditions, medical records were more likely to indicate presence 
of the condition than patient-report, while in 11 conditions, the converse was observed. This is 
the first large-scale study to examine information source in comorbidity reporting, a central issue 
in comparative effectiveness research, and highlights an important methodologic topic which 
requires further study. 
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Table 1: Characteristics of patients in this study 
Characteristic Number of Patients (N=881) % 
Age, years (median: 65, range: 41-80)   
<60 223 26 
60-69 419 49 
≥70 210 25 
Race   
White 633 72 
Nonwhite 248 28 
Marital Status   
Married 710 81 
No/unknown 171 19 
Education   
High school graduate or less 281 32 
Some college or more 589 67 
Unknown 11 1 
Income   
≤$40,000 322 37 
>$40,000 522 59 
Unknown 37 4 
NCCN Risk Group   
Low 458 52 
Intermediate 327 37 
High 94 11 
Abbreviations: PSA = prostate-specific antigen; NCCN = National Comprehensive Cancer 
Network 
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Table 2: Comparison of patient vs. physician reporting of comorbid conditions 
Comorbid 
Condition 
(AGREE) 
Patient No, 
Physician No 
N(%) 
(DISAGREE) 
Patient No, 
Physician Yes 
N(%) 
(DISAGREE) 
Patient Yes, 
Physician No 
N(%) 
(AGREE) 
Patient Yes, 
Physician Yes 
N(%) 
Overall 
Agreement 
(%) 
Kappa 
Myocardial 
Infarction 
771 (89) 10 (1) 40 (5) 47 (5) 94 0.62 
Congestive 
Heart Failure 
821 (94) 6 (1) 29 (3) 14 (2) 96 0.43 
Peripheral 
Vascular 
Disease 
821 (94) 17 (2) 21 (2) 10 (1) 95 0.32 
Cerebrovascular 
Disease 
804 (93) 18 (2) 9 (1) 38 (4) 97 0.72 
COPD  778 (90) 31 (4) 21 (2) 38 (4) 94 0.56 
Peptic Ulcer 
Disease 
773 (89) 17 (2) 65 (7) 15 (2) 91 0.23 
Liver Disease 841 (97) 10 (1) 9 (1) 10 (1) 98 0.48 
Diabetes 649 (75) 28 (3) 5 (1) 188 (22) 97 0.90 
Kidney Disease 825 (95) 14 (2) 27 (3) 4 (<1) 95 0.14 
Other Cancers 787 (91) 9 (1) 64 (7) 9 (1) 92 0.17 
HIV / AIDS 865 (100) 0 (0) 0 (0) 4 (<1) 100 1.00 
Coronary 
Artery Disease 
723 (83) 85 (10) 27 (3) 34 (4) 87 0.31 
Arrhythmia 716 (82) 17 (2) 98 (11) 39 (4) 86 0.34 
Clotting 
Disorders 
834 (96) 4 (<1) 21 (2) 10 (1) 97 0.43 
Hypertension 279 (32) 72 (8) 61 (7) 457 (53) 85 0.68 
Hyperlipidemia 281 (32) 107 (12) 172 (20) 309 (36) 68 0.36 
Inflammatory 
Bowel Disease 
848 (97) 3 (<1) 11 (1) 7 (1) 98 0.49 
Asthma  780 (90) 3 (<1) 63 (7) 24 (3) 93 0.39 
Anemia/Blood 
Disorders  
806 (93) 8 (1) 48 (6) 7 (1) 94 0.18 
Arthritis  519 (60) 14 (2) 288 (33) 48 (6) 66 0.14 
Abbreviations: COPD = chronic obstructive pulmonary disease; HIV = human 
immunodeficiency virus; AIDS = acquired immune deficiency syndrome 
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Table 3: Agreement (kappa) of comorbid conditions based on patient characteristics* 
Comorbid 
Condition 
Age Race Marital Status Education Income NCCN risk group 
<60 
(N=223) 
60-69 
(N=419) 
≥70 
(N=210) 
White 
(N=633) 
Nonwhite 
(N=248) 
Married 
(N=710) 
Other 
(N=171) 
≤HS 
(N=281) 
>HS 
(N=589) 
≤$40k 
(N=322) 
>$40k 
(N=522) 
Low 
(N=458) 
Intermediate 
(N=327) 
High 
(N=94) 
Myocardial 
Infarction 
0.65 0.66 0.53 0.61 0.68 0.63 0.59 0.65 0.61 0.62 0.64 0.69 0.46 0.79 
Congestive 
Heart Failure 
0.59 0.37 0.48 0.28 0.62 0.31 0.58 0.63 0.27 0.51 0.27 0.44 0.41 1.00 
Peripheral 
Vascular 
Disease 
0.21 0.20 0.50 0.34 0.26 0.32 0.32 0.23 0.38 0.14 0.42 
 
0.26 
 
0.38 0.38 
Cerebrovascular 
Disease 
0.94 0.69 0.67 0.70 0.75 0.71 0.73 0.70 0.74 0.68 0.79 0.75 0.66 0.78 
COPD  0.52 0.54 0.60 0.61 0.40 0.57 0.52 0.62 0.49 0.57 0.50 0.57 0.61 0.39 
PUD 0.25 0.21 0.26 0.20 0.32 0.19 0.37 0.34 0.16 0.33 0.15 0.21 0.24 0.27 
Liver Disease 0.53 0.41 0.49 0.57 0.24 0.43 0.65 0.49 0.51 0.71 0.44 0.55 0.49 0.38 
Diabetes 0.90 0.90 0.89 0.89 0.91 0.90 0.89 0.89 0.90 0.91 0.88 0.92 0.88 0.84 
Kidney Disease 0.00 0.21 0.08 0.09 0.15 0.15 0.12 0.25 -0.01 0.19 0.08 0.22 0.08 -0.02 
Other Cancers 0.09 0.19 0.19 0.20 -0.02 0.14 0.27 0.16 0.17 0.06 0.21 0.15 0.19 0.32 
HIV / AIDS 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Coronary 
Artery Disease 
0.38 0.34 0.22 0.37 0.14 0.34 0.18 0.23 0.35 0.35 0.29 0.28 0.34 0.38 
Arrhythmia 0.31 0.44 0.19 0.36 0.28 0.37 0.26 0.37 0.33 0.23 0.41 0.32 0.37 0.42 
Clotting 
Disorders 
0.60 0.24 0.41 0.36 0.60 0.47 0.31 0.59 0.31 0.56 0.38 0.30 0.61 0.55 
Hypertension 0.75 0.67 0.63 0.69 0.64 0.70 0.58 0.63 0.70 0.62 0.72 0.66 0.69 0.74 
Hyperlipidemia 0.45 0.34 0.31 0.32 0.46 0.35 0.41 0.41 0.34 0.36 0.37 0.30 0.40 0.52 
Inflammatory 
Bowel Disease 
0.40 0.70 -0.01 0.45 1.00 0.51 0.39 -0.01 0.60 0.49 0.49 0.42 0.49 0.66 
Asthma  0.48 0.38 0.37 0.35 0.50 0.39 0.39 0.47 0.35 0.46 0.31 0.26 0.48 0.71 
Anemia/Blood 
Disorders  
0.11 0.12 0.38 0.21 0.08 0.20 0.11 0.34 0.13 0.13 0.24 0.16 0.19 0.20 
Arthritis  0.20 0.11 0.13 0.11 0.20 0.12 0.20 0.14 0.14 0.12 0.17 0.12 0.13 0.26 
*A kappa difference of ≥ 0.2 among subgroups is highlighted 
Abbreviations: COPD = chronic obstructive pulmonary disease; HIV = human immunodeficiency virus; AIDS = acquired immune deficiency 
syndrome 
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Table 4: Multivariable logistic regression for agreement in each comorbid condition* 
Characteristic Myocardial 
Infarction 
CHF PVD Cerebro-
vascular  
COPD PUD Liver 
Disease 
Diabetes Kidney 
Disease 
Other 
Cancers 
Age            
<60 REF REF REF REF REF REF REF REF REF REF 
60-69 0.48 (0.19, 
1.20) 
0.35 (0.12, 
1.06) 
0.62 (0.26, 
1.52) 
0.11 (0.01, 
0.85) 
0.61 (0.28, 
1.31) 
0.62 (0.33, 
1.14) 
0.80 (0.27, 
2.37) 
0.62 (0.24, 
1.63) 
0.33 (0.12, 
0.91) 
1.09 (0.57, 
2.08) 
≥70 0.31 (0.12, 
0.80) 
0.35 (0.10, 
1.17) 
0.76 (0.27, 
2.14) 
0.10 (0.01, 
0.78) 
0.69 (0.29, 
1.68) 
0.75 (0.36, 
1.54) 
1.52 (0.35, 
6.63) 
0.78 (0.25, 
2.42) 
0.18 (0.06, 
0.52) 
0.58 (0.30, 
1.14) 
Race           
White REF REF REF REF REF REF REF REF REF REF 
Nonwhite 1.41 (0.65, 
3.05) 
0.65 (0.28, 
1.50) 
1.26 (0.56, 
2.86) 
0.86 (0.34, 
2.17) 
0.94 (0.48, 
1.86) 
1.21 (0.67, 
2.20) 
0.71 (0.24, 
2.06) 
0.88 (0.37, 
2.13) 
0.21 (0.10, 
0.43) 
1.94 (0.94, 
4.03) 
Marital Status           
Other 1.30 (0.63, 
2.71) 
1.84 (0.79, 
4.28) 
1.47 (0.67, 
3.23) 
1.47 (0.58, 
3.74) 
1.96 (1.02, 
3.76) 
0.85 (0.44, 
1.63) 
1.35 (0.41, 
4.49) 
1.37 (0.55, 
3.40) 
1.89 (0.88, 
4.05) 
1.04 (0.53, 
2.06) 
Married REF REF REF REF REF REF REF REF REF REF 
Education           
High school 
graduate or less 
1.06 (0.54, 
2.11) 
1.45 (0.61, 
3.43) 
0.64 (0.30, 
1.33) 
0.84 (0.35, 
2.03) 
0.81 (0.43, 
1.54) 
1.06 (0.61, 
1.84) 
0.80 (0.28, 
2.33) 
0.71 (0.31, 
1.63) 
0.80 (0.39, 
1.65) 
1.17 (0.64, 
2.13) 
Some college or 
more 
REF REF REF REF REF REF REF REF REF REF 
Income           
≤$40,000 REF REF REF REF REF REF REF REF REF REF 
>$40,000 1.67 (0.84, 
3.31) 
0.90 (0.42, 
2.28) 
1.61 (0.75, 
3.46) 
1.82 (0.72, 
4.65) 
1.49 (0.77, 
2.89) 
1.31 (0.75, 
2.27)  
0.38 (0.10, 
1.38) 
0.80, 0.33, 
1.90) 
0.92 (0.43, 
1.98) 
0.91 (0.50, 
1.66) 
NCCN Risk 
Group 
          
Low REF + REF REF REF REF REF REF REF REF 
Intermediate 0.75 (0.41, 
1.38) 
+ 0.87 (0.43, 
1.77) 
0.82 (0.35, 
1.91) 
1.59 (0.82, 
3.07) 
1.12 (0.68, 
1.84) 
0.69 (0.25, 
1.89) 
0.74 (0.33, 
1.66) 
0.99 (0.49, 
2.01) 
1.42 (0.83, 
2.44) 
High 2.79 (0.64, 
12.15) 
+ 1.55 (0.44, 
5.46) 
1.02 (0.27, 
3.78) 
0.93 (0.40, 
2.15) 
1.95 (0.75, 
5.10) 
0.45 (0.11, 
1.80) 
0.56 (0.19, 
1.64) 
1.18 (0.41, 
3.43) 
2.33 (0.81, 
6.71) 
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Characteristic CAD Arrhythmia Clotting Hypertension Hyperlipidemia IBD Asthma Anemia/Blood 
disorders 
Arthritis  
Age           
<60 REF REF REF REF REF REF REF REF REF 
60-69 0.55 (0.31, 
0.96) 
0.77 (0.45, 
1.33) 
0.67 (0.23, 
1.98) 
0.77 (0.47, 
1.26) 
0.78 (0.54, 1.13) 1.04 (0.24, 
4.42) 
0.56 (0.28, 
1.11) 
0.76 (0.39, 1.49) 0.74 (0.52, 
1.06) 
≥70 0.37 (0.20, 
0.67) 
0.44 (0.25, 
0.79) 
0.53 (0.17, 
1.72) 
0.71 (0.41, 
1.23) 
0.75 (0.49, 1.15) 0.54 (0.13, 
2.31) 
0.72 (0.32, 
1.63) 
1.35 (0.55, 3.28) 0.71 (0.46, 
1.07) 
Race          
White REF REF REF REF REF + REF REF REF 
Nonwhite 0.74 (0.45, 
1.22) 
0.97 (0.59, 
1.60) 
1.16 (0.40, 
3.38) 
1.07 (0.67, 
1.71) 
0.13 (0.87, 1.81) + 0.94 (0.48, 
1.81) 
0.77 (0.40, 1.49) 1.20 (0.84, 
1.72) 
Marital 
Status 
         
Other REF REF REF REF REF REF REF REF REF 
Married 2.2 (1.34, 
3.62) 
1.33 (0.80, 
2.22) 
3.05 (1.20, 
7.71) 
1.39 (0.85, 
2.25) 
0.90 (0.60, 1.34) 1.53 (0.39, 
6.04) 
1.91 (1.01, 
3.64) 
1.30 (0.65, 2.60) 0.77 (0.52, 
1.14) 
Education          
Some college 
or more 
REF REF REF REF REF REF REF REF REF 
High school 
graduate or 
less 
0.78 (0.49, 
1.24) 
0.88 (0.55, 
1.39) 
0.80 (0.32, 
2.02) 
0.86 (0.56, 
1.34) 
1.18 (0.83, 1.67) 0.70 (0.21, 
2.37) 
1.27 (0.67, 
2.39) 
2.57 (1.24, 5.33) 0.99 (0.71, 
1.39) 
Income          
≤$40,000 REF REF REF REF REF REF REF REF REF 
>$40,000 0.63 (0.38, 
1.04) 
1.13 (0.70, 
1.82) 
0.37 (0.13, 
1.07) 
1.06 (0.67, 
1.68) 
1.26 (0.88, 1.79) 0.56 (0.15, 
2.12) 
0.82 (0.43, 
1.54) 
1.57 (0.81, 3.04) 1.32 (0.94, 
1.86) 
NCCN Risk 
Group 
         
Low REF REF REF REF REF REF REF REF REF 
Intermediate 1.26 (0.81, 
1.96) 
1.40 (0.90, 
2.17) 
2.42 (0.88, 
6.67) 
1.31 (0.67, 
2.56) 
1.24 (0.90, 1.69) 1.80 (0.47, 
6.85) 
1.29 (0.74, 
2.26) 
1.74 (0.92, 3.29) 1.01 (0.74, 
1.37) 
High 2.04 (0.92, 
4.49) 
2.10, 0.96, 
4.59) 
1.21 (0.34, 
4.32) 
1.18 (0.78, 
1.79) 
1.63 (0.96, 2.75) 0.86 (0.18, 
4.21) 
2.99 (0.89, 
10.0) 
1.02 (0.43, 2.43) 1.37 (0.83, 
2.27) 
*Significant association is highlighted 
+Excluded from analysis due to insufficient number of samples in these categories 
Values are odds ratio (95% confidence interval) 
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Abbreviations: CHF = congestive heart failure; PVD = peripheral vascular disease; COPD = chronic obstructive pulmonary disease; PUD = peptic 
ulcer disease; CAD = coronary artery disease; IBD = inflammatory bowel disease
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Table 5: Number of disagreed conditions across all comorbidities per patient 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Number Percent 
0 disagreed conditions 178 20 
1 or more 698 80 
2 or more 424 48 
3 or more 232 26 
4 or more 114 13 
5 or more 55 6 
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